antibiotics
(2)
Felix Wong
Felix Wong is the co-founder and CEO of Integrated Biosciences, a Redwood City biotech using synthetic biology, optogenetics and explainable AI to discover small-molecule drugs for age-related disease. A physicist and mathematician by training with a Harvard PhD in applied physics, he led the team that reported the first new structural class of antibiotics discovered with explainable deep learning - published in Nature in 2023 - and pioneered the AI-driven discovery of senolytics. He was named to the Forbes 30 Under 30 in Healthcare and has authored more than 30 papers in journals including Nature, Science and Cell.
Michael Bigham
Michael F. Bigham is a veteran biopharmaceutical executive and investor who spent nearly a decade as Chairman and CEO of Paratek Pharmaceuticals, guiding the company through the FDA approval and commercial launch of NUZYRA (omadacycline) - a novel tetracycline-class antibiotic tackling drug-resistant bacterial infections. A Stanford MBA and CPA with roots in Gilead Sciences' early days, he has built, funded, and led companies across the full arc of drug development. He now operates as founder and managing director of Firebrand River Capital.